Taiwan’s Food and Drug Administration (FDA) emphasized that approving emergency contraception for over-the-counter sales requires public consensus. The agency cited the drug’s wide social impact and the need to consider various stakeholders. Emergency contraception has sparked discussions worldwide, especially after neighboring Japan approved over-the-counter sales.
FDA specialist Lin Yi-chu highlighted that in Taiwan, these drugs remain prescription-only. Changing their status would require input from pharmacists, advocacy groups, and parents. Lin said the agency held meetings in March and April to evaluate the issue thoroughly.
Recently, Japan’s Aska Pharmaceutical received approval to sell its emergency contraceptive, Norleveo, without a prescription. The product will require that buyers take it in the presence of a licensed pharmacist. The move has influenced Taiwan’s ongoing discussions on public access to emergency contraception.
The FDA plans to monitor Japan’s experience closely. Officials are designing local trials tailored to Taiwan’s regulatory and social context. Lin stressed that authorities aim to balance accessibility with safe usage and proper guidance.
Public and professional opinions are critical to shaping any policy change. Advocacy groups representing women, young people, and parents will be consulted. Pharmacists will provide practical feedback on handling over-the-counter sales.
Experts say broader access could help prevent unintended pregnancies. However, regulators must weigh cultural, ethical, and health considerations before permitting wider availability. Emergency contraception debates often intersect with public health, education, and societal norms.
The FDA has not set a timeline for any decision. Authorities will use trial data, regional examples, and stakeholder feedback to guide policy. In the meantime, prescription access will continue to be the primary method for obtaining emergency contraception in Taiwan.
Lin concluded that careful study and public dialogue will ensure that any future approval aligns with safety, social responsibility, and the public’s needs.
